Supplementary Materials

Supplementary Materials for:

Antagonism of EGFR and HER3 Enhances the Response to Inhibitors of the PI3K-Akt Pathway in Triple-Negative Breast Cancer

Jessica J. Tao, Pau Castel, Nina Radosevic-Robin, Moshe Elkabets, Neil Auricchio, Nicola Aceto, Gregory Weitsman, Paul Barber, Borivoj Vojnovic, Haley Ellis, Natasha Morse, Nerissa Therese Viola-Villegas, Ana Bosch, Dejan Juric, Saswati Hazra, Sharat Singh, Phillip Kim, Anna Bergamaschi, Shyamala Maheswaran, Tony Ng, Frédérique Penault-Llorca, Jason S. Lewis, Lisa A. Carey, Charles M. Perou, José Baselga,* Maurizio Scaltriti*

*Corresponding author. E-mail: scaltrim@mskcc.org (M.S.); baselgaj@mskcc.org (J.B.)

This PDF file includes:

  • Fig. S1. EGFR and PTEN abundance in HCC70 and MDA-MB-468 xenografts.
  • Fig. S2. Growth of HCC70 and MDA-MB-468 xenografts treated with MEHD7945A and PI3K-Akt pathway inhibitors.
  • Fig. S3. CEER analysis of HCC70 xenografts.
  • Fig. S4. Immunostaining for EGFR, PTEN, and Ki67 in patient-derived TNBC xenografts.
  • Fig. S5. Imaging of EGFR and HER3 in patient-derived TNBC treated with GDC-0068.
  • Fig. S6. Ki67 staining of tumors and CTCs from PDXs treated with MEHD7945A and PI3K-Akt pathway inhibitors.
  • Fig. S7. HER3 knockdown in MDA-MB-468 cells treated with GDC-0068 or GDC-0941.
  • Fig. S8. Tumor growth of HCC70 and PDXs treated with cetuximab and GDC-0068.
  • Fig. S9. Correlation between EGFR mRNA expression after cetuximab treatment and overall survival in TNBC metastatic patients.
  • Fig. S10. Quantification of HER3 abundance in paired samples from patients treated with cetuximab.
  • Fig. S11. Antibody specificity for FRET analysis.
  • Table S1. CEER values (single replicas).
  • Table S2. Patient clinicopathological information.

[Download PDF]

Technical Details

Format: Adobe Acrobat PDF

Size: 965 KB


Citation: J. J. Tao, P. Castel, N. Radosevic-Robin, M. Elkabets, N. Auricchio, N. Aceto, G. Weitsman, P. Barber, B. Vojnovic, H. Ellis, N. Morse, N. T. Viola-Villegas, A. Bosch, D. Juric, S. Hazra, S. Singh, P. Kim, A. Bergamaschi, S. Maheswaran, T. Ng, F. Penault-Llorca, J. S. Lewis, L. A. Carey, C. M. Perou, J. Baselga, M. Scaltriti, Antagonism of EGFR and HER3 Enhances the Response to Inhibitors of the PI3K-Akt Pathway in Triple-Negative Breast Cancer. Sci. Signal. 7, ra29 (2014).

© 2014 American Association for the Advancement of Science